Toshifumi Yokota

Summary

Affiliation: Children's National Medical Center
Country: USA

Publications

  1. ncbi Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy
    Toshifumi Yokota
    Children s National Medical Center, Research Center for Genetic Medicine, Washington, DC 20010, USA
    Expert Opin Biol Ther 7:831-42. 2007
  2. ncbi Optimizing exon skipping therapies for DMD
    T Yokota
    Children s National Medical Center, Center for Genetic Medicine, Washington, DC 20010, USA
    Acta Myol 26:179-84. 2007
  3. ncbi A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground
    Toshifumi Yokota
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA
    Arch Neurol 66:32-8. 2009
  4. ncbi Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy
    Toshifumi Yokota
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Avenue, NW, Washington, DC, USA
    Methods Mol Biol 709:299-312. 2011
  5. ncbi Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through
    Eric P Hoffman
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA
    Am J Pathol 179:12-22. 2011
  6. ncbi Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs
    Toshifumi Yokota
    Research Center for Genetic Medicine, Children s National Medical Center, Washington, DC 20010, USA
    Ann Neurol 65:667-76. 2009
  7. ncbi Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration
    Toshifumi Yokota
    Muscle Cell Biology Group, Medical Research Council Clinical Science Centre, Hammersmith Hospital Campus, Imperial College School of Medicine, London University, Du Cane Road, London, W12 0NN, UK
    J Cell Sci 119:2679-87. 2006
  8. ncbi Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles
    Qi Long Lu
    Muscle Cell Biology, Medical Research Council Clinical Science Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Proc Natl Acad Sci U S A 102:198-203. 2005
  9. ncbi Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene
    Miki Sakamoto
    Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi, Kodaira, Tokyo 187 8502, Japan
    Biochem Biophys Res Commun 293:1265-72. 2002
  10. ncbi Alpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration
    Yukio Hosaka
    Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi, Kodaira 187 8502, Tokyo, Japan
    J Cell Biol 158:1097-107. 2002

Collaborators

Detail Information

Publications10

  1. ncbi Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy
    Toshifumi Yokota
    Children s National Medical Center, Research Center for Genetic Medicine, Washington, DC 20010, USA
    Expert Opin Biol Ther 7:831-42. 2007
    ..This review summarizes recent progress in exon-skipping therapy and discusses future perspectives with regard to human clinical trials...
  2. ncbi Optimizing exon skipping therapies for DMD
    T Yokota
    Children s National Medical Center, Center for Genetic Medicine, Washington, DC 20010, USA
    Acta Myol 26:179-84. 2007
    ..This review summarizes recent progress in exon skipping therapy and discusses future strategies...
  3. ncbi A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground
    Toshifumi Yokota
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA
    Arch Neurol 66:32-8. 2009
    ....
  4. ncbi Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy
    Toshifumi Yokota
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Avenue, NW, Washington, DC, USA
    Methods Mol Biol 709:299-312. 2011
    ....
  5. ncbi Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through
    Eric P Hoffman
    Research Center for Genetic Medicine, Children s National Medical Center, 111 Michigan Ave NW, Washington, DC 20010, USA
    Am J Pathol 179:12-22. 2011
    ..We discuss the status of these two methods aimed at inducing de novo dystrophin production from mutant genes and review implications for other disorders...
  6. ncbi Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs
    Toshifumi Yokota
    Research Center for Genetic Medicine, Children s National Medical Center, Washington, DC 20010, USA
    Ann Neurol 65:667-76. 2009
    ..We sought to test efficacy and toxicity of intravenous oligonucleotide (morpholino)-induced exon skipping in the DMD dog model...
  7. ncbi Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration
    Toshifumi Yokota
    Muscle Cell Biology Group, Medical Research Council Clinical Science Centre, Hammersmith Hospital Campus, Imperial College School of Medicine, London University, Du Cane Road, London, W12 0NN, UK
    J Cell Sci 119:2679-87. 2006
    ..This expansion of revertant clusters depicts the cumulative history of regeneration, thus providing a useful index for functional evaluation of therapies that counteract muscle degeneration...
  8. ncbi Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles
    Qi Long Lu
    Muscle Cell Biology, Medical Research Council Clinical Science Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Proc Natl Acad Sci U S A 102:198-203. 2005
    ..We conclude that a significant therapeutic effect may be achieved by further optimization in dose and regime of administration of antisense oligonucleotide...
  9. ncbi Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene
    Miki Sakamoto
    Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi, Kodaira, Tokyo 187 8502, Japan
    Biochem Biophys Res Commun 293:1265-72. 2002
    ..These data suggest that the rod structure, and its length in particular, is crucial for the function of micro-dystrophin...
  10. ncbi Alpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration
    Yukio Hosaka
    Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4 1 1 Ogawa Higashi, Kodaira 187 8502, Tokyo, Japan
    J Cell Biol 158:1097-107. 2002
    ....